Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, diminishing the likelihood of a partnership with one most visible players in the ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Hims & Hers stock is on the upswing after the company secured a weight-loss drug partnership. Hims & Hers is acquiring its ...

Outro, which is now available in seven states, wants to help people taper off antidepressants without experiencing ...

Redburn Atlantic downgraded McDonald’s (NYSE:MCD) and launched coverage of Domino’s with a Sell rating, warning that changing consumer behavior from weight-loss drugs and pricing fatigue are emerging ...

Hims & Hers has been expanding its presence in the weight management market, with its existing Novo partnership representing ...

AnaptysBio offers significant upside, with fair value estimates nearly double its current market cap if RA approval is ...

Other readers look at health insurance 'clawbacks,' barcode voting machines, the Packaging Reduction and Recycling ...

Pharmaceutical compounding is a special way to prepare medicines. Instead of using mass-produced drugs, compounding allows ...

A federal deadline ending the sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.